Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL)

NCT01073163 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

54

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Hodgkin's Lymphoma
Mantle Cell Lymphoma

Interventions

DRUG: Bendamustine
DRUG: Rituximab

Sponsor

Cephalon